Project
ECARA
Completed ยท 2017 until 2019
Rickli Hans, Gemperle Michaela
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2017
End Date
2019
Financing
Industry
Study Design
Describe lipid parameters in patients on Evolocumab at
baseline and over 12 months in an observational real
world setting. Maintenance of LDL-c reduction over the
study period serves as surrogate for persistence with
therapy and informs us about the utility of a bi-weekly or
monthly SC application in clinical practice
Brief description/objective
Explore Clinical Utility of Evolocumab in Combination with
an e-Health System: Swiss Prospective Observational
Study in Patients with clinical Atherosclerotic
Cardiovascular Disease (ASCVD) (ECARA)